Anders L. Carlson, United States of America

International Diabetes Center Endocrinology
Anders L. Carlson, MD, is a Medical Director with the International Diabetes Center (IDC) at Park Nicollet in Minneapolis, MN, and an endocrinologist at HealthPartners and Regions Hospital in St. Paul, MN. He also serves as the Director of the Diabetes Program for HealthPartners and the Medical Director of the Stillwater Medical Group Diabetes Program. He is an associate professor at the University of Minnesota Medical School and is active in teaching medical students, residents and fellows. He is a member of the American Diabetes Association, Endocrine Society and American Association of Clinical Endocrinologists. Dr. Carlson received his MD from the University of Minnesota Medical School. He completed his internal medicine residency at Hennepin County Medical Center in Minneapolis. He trained in endocrinology and diabetes at the University of Vermont in Burlington, VT. His current research efforts are centered on diabetes technology, novel therapies for diabetes, and clinician education. He is a principal investigator on several clinical trials looking at new diabetes therapeutics focusing on hybrid closed-loop insulin pumps, insulin smart pens, and continuous glucose monitoring systems. In conjunction with the team at IDC, he has published several articles about glucose data interpretation and use of the Ambulatory Glucose Profile (AGP). In partnership with the Center for Memory and Aging at the HealthPartners Institute, he is leading a project exploring the role of intranasal insulin in hypoglycemia awareness in type 1 diabetes. He serves as an investigator on several large NIH trials including EDIC, GRADE and FLAIR. He is also participating in several quality improvement projects including the use of continuous glucose monitoring in cancer patients receiving glucocorticoids and a telehealth program with primary care, and is active with many of the national and international teaching and publication programs within the International Diabetes Center.

Presenter of 2 Presentations

 Conference Calendar
INDUSTRY SESSION

Introducing Smart MDI Therapy and overview of the integrated Insights by InPen Data Reports

Date
Thu, 03.06.2021
Session Name
Parallel Industry Symposium 09 (Not Included In The Main Event CME/CPD Credit) (ID 87)
Lecture Time
21:10 - 21:20
Presenter
Authors
PLENARY SESSION

Performance of studies on advance hybrid closed-loop 780G

Date
Fri, 04.06.2021
Session Name
0170 - Live Q&A: Plenary Session 03: Advances In Closed-Loop Systems – Lessons Learnt From Clinical Studies (ID 19)
Lecture Time
18:35 - 18:55
Presenter
Authors

Abstract

Abstract Body

There have been major advancements in automated insulin delivery systems in the past several years, with hybrid closed-loop systems offering patients new means to manage their diabetes. Such systems rely on algorithms to modulate the insulin delivery, increasing or decreasing insulin delivery based upon programed target glucose, patient-entered carbohydrates and correction boluses that can be user or device initiated. The MiniMedTM Advanced Hybrid Closed Loop (AHCL) system, or MiniMedTM 780G, is a new iteration of pump therapy that has a target set point of either 100 mg/dL (5.6 mmol/L) or 120 mg/dL (6.7 mmol/L), along with automated corrections that can deliver boluses every 5 minutes as needed.

The MiniMedTM 780G system has been studied for safety and efficacy in recent trials. The largest trial was a multi-site pivotal trial of 39 adolescents (age 14-21 years) and 118 adults (>22 years) during which patients with type 1 diabetes used either the 100 mg/dL or 120 mg/dL set point for approximately 45 days, and then crossed over to the other set point for another period of about 45 days. For the overall study group, time in range (70-180 mg/dL/ 3.9 mmol/L-10 mmol/L) increased from 68.8% to 74.5% (p = 0.001). For those using the set point of 100 mg/dL and an active insulin time of 2 hours, time in range increased to 78.8%. Auto Mode was in use for 95% of the time for both set points during the study. Of the total bolus insulin delivered during the study, approximately 22% of this was administered by the auto-correction function. Time in hypoglycemia was reduced in both adolescents and adults, and there were no DKA or severe hypoglycemia events.

Additional studies have compared the MiniMedTM 780G system against both the first commercially available hybrid closed-loop system in the United States, the MiniMedTM 670G, and to a system with predictive low glucose threshold suspend MiniMedTM 640G. Both studies concluded the AHCL system provided improved glycemic control without increasing time in hypoglycemia.

The MiniMedTM 780G has consistently demonstrated improved time in range without increasing time below range, and has been safe in the trials to date. The system also seemed to have improved user experience with patient-selected targets and fewer Auto Mode exits.

Hide